Some nonsteroidal anti-inflammatory drugs (NSAIDs), including cyclooxygenase-2 selective
inhibitors, have been associated with increased cardiovascular (CV) events in recent clinical …

Objectives To examine whether the increased risk of cardiovascular events with rofecoxib
represents a class effect of cyclooxygenase-2 (COX-2) specific inhibitors. Design Systematic …

In a very short time, COX-2 enzyme inhibitors have gone from the darlings to the pariahs of
the pharmaceutical industry. These drugs were developed based on the hypothesis …

The seminal epidemiological observation that nonsteroidal anti-inflammatory drugs
(NSAIDs) prevent colon and possibly other cancers has spurred novel approaches to cancer …

Nonselective cyclooxygenase (COX) inhibitors target many of the same cancer-associated
molecular pathways as COX-2–specific inhibitors. Although these nonsteroidal anti …

Background Selective cyclooxygenase inhibitors may retard the progression of cancer, but
they have enhanced thrombotic potential. We report on cardiovascular adverse events in …

Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely used
prescription and nonprescription drugs in the world. The discovery of cyclooxygenase (COX) …

Recent research has drawn attention to protective effects of chemopreventive agents that
reverse, suppress, or prevent the carcinogenic progression using pharmacological or …

Atherosclerosis is a process with inflammatory features and selective cyclooxygenase 2
(COX-2) inhibitors may potentially have antiatherogenic effects by virtue of inhibiting …

Background—The cardiovascular safety of cyclooxygenase (COX)-2–selective nonsteroidal
antiinflammatory drugs (NSAIDs) has come under scrutiny after the withdrawal of rofecoxib …